The Europe Live Biotherapeutic Products And Microbiome CDMO Market should witness market growth of 43.1% CAGR during the forecast period (2023-2029).
The fundamental tenet of the quickly developing discipline of microbiome therapeutics is utilizing the naturally developed medicinal capabilities of gut bacteria to produce desired clinical results/advantages. Furthermore, in recent years, the medical science field has been quite excited about the promising discoveries from microbiome-focused research, which provides a fresh viewpoint on personalized therapy. Given the active ingredients that are now being employed, this particular class of medications exists at the intersection of naturopathic treatments and clinically validated measures, having proven their capacity to provide real, quantifiable therapeutic effects.
The development of microbiome-based medicines for the treatment of a variety of ailments is reportedly being undertaken by many businesses, including public as well as private parties. The desire to collaborate with early-stage inventors in this field has also been shown by several significant pharmaceutical companies. Having said that, the majority of these projects are either in early-phase clinical trials or remain in the preclinical phases. Phase II/III trials are underway for several microbiome-based product candidates expected to fuel the market's expansion in the coming years.
LBPs do not now have a "separate status" inside the European legal system. Since live microorganisms - which are biological substances - are the active ingredients in LBPs, these drugs are, by definition, called biological, medical products. The legal and regulatory framework for biological and medical products must therefore be complied with by LBPs. According to recent data, inflammatory bowel illnesses [IBD] are still becoming more common and common across the region. Currently, IBD affects 0.2% of the population in Europe. With a focus on strict objective monitoring of the progression of the disease and a treat-to-target strategy in Europe, medical therapy, as well as disease management, have undergone tremendous change in recent decades with the aim of preventing early bowel disability and damage. Therefore, the rising need for the development of LBPs for treating IBD is responsible for the expansion of the regional market.
The Germany market dominated the Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022; thereby, achieving a market value of $5,950.7 Thousands by 2029. The UK market is registering a CAGR of 41.9% during (2023-2029). Additionally, The France market would showcase a CAGR of 44.2% during (2023-2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
The fundamental tenet of the quickly developing discipline of microbiome therapeutics is utilizing the naturally developed medicinal capabilities of gut bacteria to produce desired clinical results/advantages. Furthermore, in recent years, the medical science field has been quite excited about the promising discoveries from microbiome-focused research, which provides a fresh viewpoint on personalized therapy. Given the active ingredients that are now being employed, this particular class of medications exists at the intersection of naturopathic treatments and clinically validated measures, having proven their capacity to provide real, quantifiable therapeutic effects.
The development of microbiome-based medicines for the treatment of a variety of ailments is reportedly being undertaken by many businesses, including public as well as private parties. The desire to collaborate with early-stage inventors in this field has also been shown by several significant pharmaceutical companies. Having said that, the majority of these projects are either in early-phase clinical trials or remain in the preclinical phases. Phase II/III trials are underway for several microbiome-based product candidates expected to fuel the market's expansion in the coming years.
LBPs do not now have a "separate status" inside the European legal system. Since live microorganisms - which are biological substances - are the active ingredients in LBPs, these drugs are, by definition, called biological, medical products. The legal and regulatory framework for biological and medical products must therefore be complied with by LBPs. According to recent data, inflammatory bowel illnesses [IBD] are still becoming more common and common across the region. Currently, IBD affects 0.2% of the population in Europe. With a focus on strict objective monitoring of the progression of the disease and a treat-to-target strategy in Europe, medical therapy, as well as disease management, have undergone tremendous change in recent decades with the aim of preventing early bowel disability and damage. Therefore, the rising need for the development of LBPs for treating IBD is responsible for the expansion of the regional market.
The Germany market dominated the Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022; thereby, achieving a market value of $5,950.7 Thousands by 2029. The UK market is registering a CAGR of 41.9% during (2023-2029). Additionally, The France market would showcase a CAGR of 44.2% during (2023-2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
Scope of the Study
By Application
- C.difficile
- Crohns Disease
- IBS
- Diabetes
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
- Cerbios-Pharma SA
- Biose Industrie
- List Biological Laboratories, Inc.
- AcuraBio Pty Ltd (Ampersand Capital Partners)
- Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
- Quay Pharmaceuticals Ltd (SGS S.A.)
- BiomX, Inc.
- Lonza Group AG
- 4D Pharma Plc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application
Chapter 4. Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country
Chapter 5. Company Profiles
Companies Mentioned
- Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
- Cerbios-Pharma SA
- Biose Industrie
- List Biological Laboratories, Inc.
- AcuraBio Pty Ltd (Ampersand Capital Partners)
- Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
- Quay Pharmaceuticals Ltd (SGS S.A.)
- BiomX, Inc.
- Lonza Group AG
- 4D Pharma Plc
Methodology
LOADING...
